缬更昔洛韦用于抑制爱泼斯坦-巴尔病毒复制。
Valganciclovir for the Suppression of Epstein-Barr Virus Replication.
作者信息
Yager Jessica E, Magaret Amalia S, Kuntz Steven R, Selke Stacy, Huang Meei-Li, Corey Lawrence, Casper Corey, Wald Anna
机构信息
Department of Medicine, State University of New York Downstate Medical Center, Brooklyn.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
出版信息
J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.
Abstract
Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative treatment. Valganciclovir reduced the proportion of days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.41; P < .001), and quantity of virus detected by 0.77 logs (95% CI, .62-.91 logs; P < .001). Further investigations into the impact of valganciclovir on EBV-associated diseases are needed.
摘要
爱泼斯坦-巴尔病毒（EBV）可引起传染性单核细胞增多症，并可能导致淋巴增殖性疾病。我们在一项随机、双盲、安慰剂对照研究中评估了缬更昔洛韦对口腔EBV脱落的影响。26名男性接受了为期8周的口服缬更昔洛韦或每日安慰剂治疗，随后是为期2周的“洗脱期”，然后接受8周的替代治疗。缬更昔洛韦将检测到EBV的天数比例从61.3%降至17.8%（相对风险，0.28；95%置信区间[CI]，0.21 - 0.41；P < .001），检测到的病毒量减少了0.77对数（95% CI，0.62 - 0.91对数；P < .001）。需要进一步研究缬更昔洛韦对EBV相关疾病的影响。
相似文献
1
Valganciclovir for the Suppression of Epstein-Barr Virus Replication.缬更昔洛韦用于抑制爱泼斯坦-巴尔病毒复制。
J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.
2
Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.对肾脏供体给予缬更昔洛韦以减轻移植过程中巨细胞病毒和爱泼斯坦-巴尔病毒传播的负担。
Transplantation. 2015 Jun;99(6):1186-91. doi: 10.1097/TP.0000000000000490.
3
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.缬更昔洛韦抑制人疱疹病毒8型复制的随机、双盲、安慰剂对照、交叉试验。
J Infect Dis. 2008 Jul 1;198(1):23-30. doi: 10.1086/588820.
4
Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.缬更昔洛韦抑制来氟米特免疫抑制期间的 EBV 再激活。
J Clin Virol. 2014 Apr;59(4):255-8. doi: 10.1016/j.jcv.2014.01.005. Epub 2014 Jan 18.
5
Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.缬更昔洛韦对感染EB病毒的肝移植儿童的疗效及安全性
Liver Transpl. 2008 Aug;14(8):1185-93. doi: 10.1002/lt.21498.
6
A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.一项比较更昔洛韦与更昔洛韦加免疫球蛋白预防爱泼斯坦-巴尔病毒相关移植后淋巴细胞增生性疾病的随机试验。
Transplantation. 2006 Mar 27;81(6):856-61. doi: 10.1097/01.tp.0000202724.07714.a2.
7
Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.缬更昔洛韦对小儿肝移植中爱泼斯坦-巴尔病毒聚合酶链反应的影响：初步报告。
Transplant Proc. 2009 Apr;41(3):1038-40. doi: 10.1016/j.transproceed.2009.02.053.
8
Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.慢性疲劳综合征患者人疱疹病毒 6 和 Epstein-Barr 病毒 IgG 抗体滴度对缬更昔洛韦的反应。
J Med Virol. 2012 Dec;84(12):1967-74. doi: 10.1002/jmv.23411.
9
Unusual presentation of Epstein-Barr virus hepatitis treated successfully with valganciclovir.EB 病毒肝炎的不典型表现经缬更昔洛韦治疗成功。
J Med Virol. 2014 Mar;86(3):484-6. doi: 10.1002/jmv.23766. Epub 2013 Sep 30.
10
Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.一项评估伐昔洛韦在慢性疲劳综合征患者亚组中的疗效和安全性的随机临床试验。
J Med Virol. 2013 Dec;85(12):2101-9. doi: 10.1002/jmv.23713. Epub 2013 Aug 19.
引用本文的文献
1
Vaxtherapy, a Multiphase Therapeutic Protocol Approach for Longvax, the COVID-19 Vaccine-Induced Disease: Spike Persistence as the Core Culprit and Its Downstream Effects.疫苗疗法，一种针对新冠疫苗诱导疾病Longvax的多阶段治疗方案：刺突蛋白持续存在作为核心罪魁祸首及其下游影响
Diseases. 2025 Jun 30;13(7):204. doi: 10.3390/diseases13070204.
2
The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.先驱转录因子、染色质可及性和表观遗传重编程在致癌病毒中的作用。
Front Microbiol. 2025 Jun 16;16:1602497. doi: 10.3389/fmicb.2025.1602497. eCollection 2025.
3
The critical role of ferroptosis in virus-associated hematologic malignancies and its potential value in antiviral-antitumor therapy.铁死亡在病毒相关血液系统恶性肿瘤中的关键作用及其在抗病毒抗肿瘤治疗中的潜在价值。
Virulence. 2025 Dec;16(1):2497908. doi: 10.1080/21505594.2025.2497908. Epub 2025 Apr 29.
4
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.重新利用对爱泼斯坦-巴尔病毒有活性的已获许可药物治疗多发性硬化症：一种系统方法。
CNS Drugs. 2025 Mar;39(3):305-320. doi: 10.1007/s40263-024-01153-5. Epub 2025 Jan 10.
5
Lights and Shadows of Long COVID: Are Latent Infections the Real Hidden Enemy?长期新冠的光影：潜伏感染是真正的隐藏敌人吗？
J Clin Med. 2024 Nov 25;13(23):7124. doi: 10.3390/jcm13237124.
6
Mechanisms of long COVID and the path toward therapeutics.长新冠的发病机制和治疗方法研究进展。
Cell. 2024 Oct 3;187(20):5500-5529. doi: 10.1016/j.cell.2024.07.054. Epub 2024 Sep 25.
7
Effects of ganciclovir combined with recombinant human interferon-α on clinical efficacy and immune function in children with infectious mononucleosis.更昔洛韦联合重组人干扰素α对传染性单核细胞增多症患儿临床疗效及免疫功能的影响
Pak J Med Sci. 2024 Aug;40(7):1473-1478. doi: 10.12669/pjms.40.7.8705.
8
High malignancy rate in the absence of viral prophylaxis after kidney transplantation in Sudan.苏丹肾移植后无病毒预防的高恶性肿瘤发生率。
J Nephrol. 2024 Jul;37(6):1653-1659. doi: 10.1007/s40620-024-01978-9. Epub 2024 Jun 7.
9
Urinary Viral Spectrum in Patients with Interstitial Cystitis/Bladder Pain Syndrome and the Clinical Efficacy of Valacyclovir Treatment.间质性膀胱炎/膀胱疼痛综合征患者的尿液病毒谱及伐昔洛韦治疗的临床疗效
Biomedicines. 2024 Feb 26;12(3):522. doi: 10.3390/biomedicines12030522.
10
Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.当前实体器官移植受者疱疹病毒感染管理的观点。
Viruses. 2023 Jul 21;15(7):1595. doi: 10.3390/v15071595.
本文引用的文献
1
Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection.在HIV感染早期阶段开始抗逆转录病毒治疗期间，人类疱疹病毒的复制与更高的HIV DNA水平相关。
J Virol. 2016 Mar 28;90(8):3944-3952. doi: 10.1128/JVI.02638-15. Print 2016 Apr.
2
Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.缬更昔洛韦抑制来氟米特免疫抑制期间的 EBV 再激活。
J Clin Virol. 2014 Apr;59(4):255-8. doi: 10.1016/j.jcv.2014.01.005. Epub 2014 Jan 18.
3
Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.伐昔洛韦、泛昔洛韦或抗逆转录病毒治疗可降低 HIV-1 血清阳性男性的人类疱疹病毒-8 复制。
J Med Virol. 2011 Oct;83(10):1696-703. doi: 10.1002/jmv.22194.
4
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.缬更昔洛韦可降低接受抗逆转录病毒治疗但 CD4+T 细胞恢复不完全的 HIV 感染者的 T 细胞活化。
J Infect Dis. 2011 May 15;203(10):1474-83. doi: 10.1093/infdis/jir060.
5
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.80 例实体器官移植后发生移植后淋巴组织增生性疾病患者的多中心分析：现代时代的结局和预后因素。
J Clin Oncol. 2010 Feb 20;28(6):1038-46. doi: 10.1200/JCO.2009.25.4961. Epub 2010 Jan 19.
6
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.缬更昔洛韦抑制人疱疹病毒8型复制的随机、双盲、安慰剂对照、交叉试验。
J Infect Dis. 2008 Jul 1;198(1):23-30. doi: 10.1086/588820.
7
Oral mucosal reactivation rates of herpesviruses among HIV-1 seropositive persons.HIV-1血清阳性者中疱疹病毒的口腔黏膜再激活率。
J Med Virol. 2008 Jul;80(7):1153-9. doi: 10.1002/jmv.21214.
8
A virologic pilot study of valacyclovir in infectious mononucleosis.伐昔洛韦治疗传染性单核细胞增多症的病毒学初步研究。
J Clin Virol. 2007 May;39(1):16-21. doi: 10.1016/j.jcv.2007.02.002. Epub 2007 Mar 21.
9
Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.更昔洛韦和阿昔洛韦可降低肾移植受者移植后淋巴细胞增生性疾病的风险。
Am J Transplant. 2005 Dec;5(12):2894-900. doi: 10.1111/j.1600-6143.2005.01115.x.
10
Persistence of the Epstein-Barr virus and the origins of associated lymphomas.爱泼斯坦-巴尔病毒的持续存在与相关淋巴瘤的起源
N Engl J Med. 2004 Mar 25;350(13):1328-37. doi: 10.1056/NEJMra032015.
Zotero 插件